Find key information on ovarian cancer diagnosis history including ICD-10 codes, clinical documentation requirements, staging, CA-125 levels, pathology reports, diagnostic imaging, and treatment history. Learn about risk factors, genetic predisposition, family history documentation, and symptoms related to ovarian cancer diagnosis. This resource provides valuable information for healthcare professionals, medical coders, and patients seeking to understand the process of ovarian cancer diagnosis.
Also known as
Personal history of malignant neoplasm of ovary
Indicates a past diagnosis of ovarian cancer.
Malignant neoplasm of ovary
Used for active ovarian cancer, not history.
Factors influencing health status
Broad category including personal history of diseases.
Follow this step-by-step guide to choose the correct ICD-10 code.
Is the ovarian cancer currently active?
Yes
Primary or secondary?
No
Personal history or family history?
When to use each related code
| Description |
|---|
| Ovarian cancer |
| Ovarian cyst |
| Pelvic inflammatory disease (PID) |
Coding ovarian cancer without specifying laterality (right, left, bilateral) can lead to inaccurate staging and treatment data.
Misclassifying primary ovarian cancer vs. metastasis from another site can affect treatment and statistical reporting.
Incorrectly coding a history of ovarian cancer as active disease impacts quality metrics and resource allocation.
Q: What are the key historical milestones in ovarian cancer diagnosis and how have they impacted current clinical practice?
A: Several key milestones have shaped our approach to ovarian cancer diagnosis. Early advancements involved rudimentary pelvic examinations and exploratory surgery, which offered limited diagnostic accuracy. The development of CA-125 as a tumor marker in the 1980s represented a significant step, although its sensitivity and specificity particularly in early stages remain a challenge. Transvaginal ultrasound (TVUS) emerged as a crucial imaging modality, allowing for improved visualization of the ovaries. More recently, advances in imaging techniques like Doppler ultrasound and MRI, along with novel biomarkers and genetic testing (BRCA1/2, Lynch syndrome), offer greater potential for earlier detection and personalized risk assessment. These historical developments underscore the evolution from primarily symptom-driven diagnosis to a more nuanced, technology-driven approach, striving for earlier and more accurate identification of ovarian cancer. Explore how incorporating these advancements can enhance your diagnostic accuracy in clinical practice.
Q: How has the understanding of premalignant ovarian lesions and their progression to ovarian cancer evolved over time, impacting screening and management strategies?
A: Our understanding of premalignant ovarian lesions, such as serous tubal intraepithelial carcinoma (STIC) and ovarian intraepithelial neoplasia (IEN), has significantly advanced. Historically, these lesions were often overlooked or understudied. Increasing evidence now suggests that a significant proportion of high-grade serous ovarian cancers may originate in the fallopian tubes, emphasizing the importance of STIC. This shift in understanding has influenced risk-reducing salpingectomy as a preventative strategy in high-risk individuals. Furthermore, ongoing research focuses on identifying specific molecular markers and genetic alterations within these premalignant lesions to improve early detection and risk stratification. Consider implementing updated screening and management guidelines that reflect this evolving understanding of the origins and progression of ovarian cancer. Learn more about the role of STIC and other premalignant lesions in contemporary ovarian cancer management.
Patient presents with a history of ovarian cancer, diagnosed in [Month, Year] at age [Age at Diagnosis]. The primary site was [Ovarian Primary Site - e.g., right ovary, left ovary, bilateral ovaries] and the histologic type was [Histologic Type - e.g., serous adenocarcinoma, endometrioid carcinoma, clear cell carcinoma]. The stage at diagnosis was [Stage - e.g., I, II, III, IV] using the FIGO staging system. Initial treatment included [Treatment Details - e.g., debulking surgery, total abdominal hysterectomy, bilateral salpingo-oophorectomy, chemotherapy with carboplatin and paclitaxel]. The patient achieved [Response to Treatment - e.g., complete remission, partial remission, stable disease, progressive disease] following initial therapy. Current surveillance includes [Surveillance Modalities - e.g., physical exam, CA-125 levels, imaging studies such as CT scans or transvaginal ultrasound]. The patient reports [Current Symptoms - e.g., asymptomatic, abdominal pain, bloating, fatigue]. Physical examination reveals [Physical Exam Findings - e.g., normal abdominal exam, palpable mass, ascites]. Assessment includes history of ovarian cancer, [Current Disease Status - e.g., in remission, recurrent disease, progressive disease]. Plan includes [Plan for Future Care - e.g., continued surveillance, chemotherapy, referral to oncology, palliative care]. Differential diagnoses at the time of initial diagnosis included [Differential Diagnoses - e.g., benign ovarian cyst, pelvic inflammatory disease, endometriosis]. Relevant medical history includes [Other Medical History - e.g., hypertension, diabetes, family history of ovarian cancer]. Current medications include [Current Medications]. Allergies include [Allergies]. Ovarian cancer diagnosis ICD-10 code [ICD-10 Code - e.g., C56.9] is documented for medical billing and coding purposes.